NetworkNewsBreaks – CytoDyn Inc. (CYDY) Submits
Post# of 148338
(Total Views: 134)
Posted On: 11/05/2018 4:07:28 PM
NetworkNewsBreaks – CytoDyn Inc. (CYDY) Submits IND Application, Protocol for Phase 1b/2 Clinical Trial with PRO 140
CytoDyn (OTCQB: CYDY) this morning announced its submission of an investigational new drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) to carry out a phase 1b/2 clinical trial with PRO 140 as a therapy for metastatic triple-negative breast cancer. Currently, limited therapeutic options are available for triple-negative breast cancer due to an absence of standard biomarkers for targeted options. The original research and issued patents on CCR5 as a therapeutic target for cancer treatment were led by Richard Pestell, M.D., Ph.D., CytoDyn’s Interim Chief Medical Officer. Dr. Pestell’s published conclusions verified that CCR5 is a crucial receptor in the growth, invasion and metastasis of human cancers. PRO 140, a CCR5 antagonist, has recently demonstrated obstruction of human breast cancer cell invasion and colon cancer tumor growth.
“We are honored to have Dr. Pestell lead this effort by overseeing the advancement of PRO 140 in this indication and other planned oncology and autoimmune disease studies,” Nader Pourhassan, Ph.D., CytoDyn’s President and Chief Executive Officer stated in the news release. “If the early analysis of the trial will demonstrate positive clinical activity, CytoDyn expects to file for breakthrough therapy designation. During the study, a number of correlative studies will be measured to better understand the mode of action of PRO 140, primarily circulating tumor cells (“CTC”). CTC promotes metastasis and metastasis is the leading cause of death of cancer patients. If PRO 140 decreases the CTC by blocking the CCR5 receptor, then we believe PRO 140 may have the potential to disrupt the current standard of care treatments in a variety of cancer indications.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
CytoDyn (OTCQB: CYDY) this morning announced its submission of an investigational new drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) to carry out a phase 1b/2 clinical trial with PRO 140 as a therapy for metastatic triple-negative breast cancer. Currently, limited therapeutic options are available for triple-negative breast cancer due to an absence of standard biomarkers for targeted options. The original research and issued patents on CCR5 as a therapeutic target for cancer treatment were led by Richard Pestell, M.D., Ph.D., CytoDyn’s Interim Chief Medical Officer. Dr. Pestell’s published conclusions verified that CCR5 is a crucial receptor in the growth, invasion and metastasis of human cancers. PRO 140, a CCR5 antagonist, has recently demonstrated obstruction of human breast cancer cell invasion and colon cancer tumor growth.
“We are honored to have Dr. Pestell lead this effort by overseeing the advancement of PRO 140 in this indication and other planned oncology and autoimmune disease studies,” Nader Pourhassan, Ph.D., CytoDyn’s President and Chief Executive Officer stated in the news release. “If the early analysis of the trial will demonstrate positive clinical activity, CytoDyn expects to file for breakthrough therapy designation. During the study, a number of correlative studies will be measured to better understand the mode of action of PRO 140, primarily circulating tumor cells (“CTC”). CTC promotes metastasis and metastasis is the leading cause of death of cancer patients. If PRO 140 decreases the CTC by blocking the CCR5 receptor, then we believe PRO 140 may have the potential to disrupt the current standard of care treatments in a variety of cancer indications.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼